Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

More active mitochondria may help chronic myeloid leukemia cells withstand treatment (opens in a new tab)

medicalxpress.com · 2026-10-12

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 5 supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly supported

Every claim we could check holds up. Five of six claims match the study. This overall rating is based only on the claims we could check. One claim the study doesn't address.

  • 5 supported
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredIn preclinical experiments, a mitochondrial inhibitor reduced the ability of CML stem and progenitor cells to grow and survive, and the effect was stronger when combined with imatinib, almost eliminating colony formation entirely.View evidenceHide evidence

As statedalmost eliminating colony formation entirely

Why this verdict

The abstract supports the core direction that pharmacologic Complex I inhibition reduced clonogenic potential and enhanced imatinib sensitivity. However, at abstract depth it does not provide the inhibitor identity, sample/cell-type details, quantitative effect sizes, or support for the specific magnitude claim that colony formation was 'almost eliminated entirely.' It also does not clearly establish from the abstract alone whether the assays were specifically in CML stem/progenitor cells rather than other CML cells.

1

Study evidence

Pharmacologic Complex I inhibition reduced clonogenic potential and enhanced imatinib sensitivity.

“Pharmacologic Complex I inhibition reduced clonogenic potential and enhanced imatinib sensitivity.”
Claim 2 of 6SupportedResearchers in Adelaide and Singapore uncovered clues as to why some people with chronic myeloid leukemia respond better to treatment than others, finding that mitochondrial function in cancer cells could be targeted to improve responses.View evidenceHide evidence

Why this verdict

The abstract-level profile supports an association between mtDNA mutation measures/metabolic phenotypes and imatinib response, and it reports ex vivo Complex I inhibition reducing clonogenic potential and enhancing imatinib sensitivity. The story frames this as clues and a possible target to improve response, which is appropriately hedged rather than claiming clinical efficacy.

1

Study evidence

In the clinically annotated cohort of 79 imatinib-treated CML patients, a higher number of mtDNA mutations (≥3) and higher variant allele frequency were associated with superior molecular responses, and these associations remained significant after multivariable adjustment.

“In a clinically annotated cohort of 79 imatinib-treated patients, a higher number of mtDNA mutations (≥3 mutations) and higher variant allele frequency were associated with superior molecular responses, and remained significant in multivariable analyses.”
2

Study evidence

Suboptimal imatinib responders exhibited increased mitochondrial respiration, spare respiratory capacity, mitochondrial content, and enrichment of mitochondrial biogenesis and lipid metabolic programs, consistent with enhanced oxidative phosphorylation dependence.increased

“mtDNA mutational patterns were associated with distinct metabolic phenotypes in CD34+ leukemic stem/progenitor cells.”
Claim 3 of 6SupportedPublished in HemaSphere, the study examined mitochondrial DNA mutations in 120 patients with chronic-phase CML and reported a relationship between mitochondrial genetics, cancer cell metabolism, and responses to treatment.View evidenceHide evidence

As stated120 patients

Why this verdict

The profile states that 120 chronic-phase CML patients underwent comprehensive somatic mtDNA profiling and that mtDNA mutational patterns were linked to metabolic phenotypes and imatinib response. The clinical response association was specifically reported in a clinically annotated subset of 79 imatinib-treated patients, so the story is acceptable so long as the 120-patient figure is read as the mtDNA profiling cohort rather than the response-analysis sample.

1

Study evidence

In diagnostic samples from 120 chronic‑phase CML patients, 241 somatic mtDNA mutations were identified in 92 patients; 29 mutations were homoplasmic.241 somatic mtDNA mutations; 29 homoplasmic; mutations present in 92/120 patients

“We performed comprehensive profiling of somatic mtDNA mutations in 120 patients with chronic-phase CML.”
2

Study evidence

In the clinically annotated cohort of 79 imatinib-treated CML patients, a higher number of mtDNA mutations (≥3) and higher variant allele frequency were associated with superior molecular responses, and these associations remained significant after multivariable adjustment.

“In a clinically annotated cohort of 79 imatinib-treated patients, a higher number of mtDNA mutations (≥3 mutations) and higher variant allele frequency were associated with superior molecular responses, and remained significant in multivariable analyses.”
Claim 4 of 6SupportedThe cells from patients with poorer responses appeared to have fitter, more active mitochondria, which may give them the energy and flexibility to survive treatment pressure.View evidenceHide evidence

Why this verdict

The profile reports that suboptimal responders had increased mitochondrial respiration, spare respiratory capacity, mitochondrial content, and enrichment of mitochondrial biogenesis/lipid metabolic programs, consistent with more active or fitter mitochondria. The statement that this may provide energy/flexibility to survive treatment pressure is interpretive but hedged and aligned with the reported oxidative phosphorylation dependence.

1

Study evidence

Suboptimal imatinib responders exhibited increased mitochondrial respiration, spare respiratory capacity, mitochondrial content, and enrichment of mitochondrial biogenesis and lipid metabolic programs, consistent with enhanced oxidative phosphorylation dependence.increased

“mtDNA mutational patterns were associated with distinct metabolic phenotypes in CD34+ leukemic stem/progenitor cells.”
Claim 5 of 6SupportedLeukemia cells from poorer responders relied more heavily on mitochondrial energy production, revealing a potential therapeutic vulnerability.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that suboptimal responders showed enhanced oxidative phosphorylation dependence and that Complex I inhibition reduced clonogenic potential and enhanced imatinib sensitivity. Describing this as a potential therapeutic vulnerability is consistent with the paper’s framing.

1

Study evidence

Suboptimal imatinib responders exhibited increased mitochondrial respiration, spare respiratory capacity, mitochondrial content, and enrichment of mitochondrial biogenesis and lipid metabolic programs, consistent with enhanced oxidative phosphorylation dependence.increased

“mtDNA mutational patterns were associated with distinct metabolic phenotypes in CD34+ leukemic stem/progenitor cells.”
2

Study evidence

Pharmacologic Complex I inhibition reduced clonogenic potential and enhanced imatinib sensitivity.

“Pharmacologic Complex I inhibition reduced clonogenic potential and enhanced imatinib sensitivity.”
Claim 6 of 6SupportedThe authors say the work is proof of concept that disrupting how these cancer cells generate energy may improve responses to existing TKI therapies and could help identify patients less likely to respond well to imatinib.View evidenceHide evidence

Why this verdict

The profile supports a proof-of-concept interpretation: mtDNA/metabolic features are candidate biomarkers of imatinib response, and Complex I inhibition enhanced imatinib sensitivity ex vivo. The claim is appropriately speculative and hedged. The evidence is strongest for imatinib specifically; broader implications for existing TKI therapies remain a future-oriented extrapolation.

1

Study evidence

In the clinically annotated cohort of 79 imatinib-treated CML patients, a higher number of mtDNA mutations (≥3) and higher variant allele frequency were associated with superior molecular responses, and these associations remained significant after multivariable adjustment.

“In a clinically annotated cohort of 79 imatinib-treated patients, a higher number of mtDNA mutations (≥3 mutations) and higher variant allele frequency were associated with superior molecular responses, and remained significant in multivariable analyses.”
2

Study evidence

Suboptimal imatinib responders exhibited increased mitochondrial respiration, spare respiratory capacity, mitochondrial content, and enrichment of mitochondrial biogenesis and lipid metabolic programs, consistent with enhanced oxidative phosphorylation dependence.increased

“mtDNA mutational patterns were associated with distinct metabolic phenotypes in CD34+ leukemic stem/progenitor cells.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The abstract does not provide quantitative effect sizes, sample sizes, inhibitor identity, concentrations, treatment durations, or formal synergy/additivity metrics for the Complex I inhibition experiments.

    This limitation is material because the story adds a strong quantitative-sounding claim that combination treatment 'almost eliminated colony formation entirely.' The story mentions the experiments were preclinical but does not acknowledge that the abstract-level evidence lacks quantitative details needed to verify that magnitude.

    From ex_vivo_human

  • The abstract omits technical details needed to fully evaluate mtDNA variant calling and cohort selection, including sequencing platform/depth, matched germline strategy, filters, homoplasmy/heteroplasmy thresholds, and patient demographic/clinical selection criteria.

    The story does not mention these abstract-level methodological limitations. They are relevant to confidence in the mtDNA-mutation profiling but are not central to the story’s main therapeutic framing.

    From secondary_data / observational sequencing cohort

5 things the story did carry across
  • The paper profiled somatic mtDNA mutations in 120 chronic-phase CML patients at diagnosis and identified 241 somatic mtDNA mutations in 92 patients, including 29 homoplasmic mutations.
  • The clinically annotated imatinib-response analysis was performed in a subset of 79 imatinib-treated patients, where higher mtDNA mutation burden and higher variant allele frequency were associated with superior molecular responses and remained significant in multivariable analyses.
  • Suboptimal responders’ CD34+ leukemic stem/progenitor cells showed increased mitochondrial respiration, spare respiratory capacity, mitochondrial content, and mitochondrial biogenesis/lipid metabolic programs, while favorable responders had higher mtDNA mutational burden, reduced respiratory reserve, and increased mitophagy-related programs.
  • Pharmacologic mitochondrial Complex I inhibition reduced clonogenic potential and enhanced imatinib sensitivity in ex vivo/preclinical assays.
  • The abstract-level evidence does not establish clinical causality between mtDNA mutations, mitochondrial metabolic state, and patient response; key response findings are observational and the inhibitor findings are ex vivo/preclinical.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataDefine the somatic mtDNA mutational landscape in chronic-phase CML at diagnosis and relate mtDNA mutation burden/allele fraction to molecular response to imatinib in a clinically annotated cohort.Clinically annotated observational cohort (imatinib-treated patients)Expand

In plain English

In chronic-phase CML, somatic mtDNA mutations were profiled and, in a clinically annotated subgroup of 79 imatinib-treated patients, a higher mtDNA mutation burden (≥3 mutations) and higher variant allele frequency were associated with superior molecular responses; these associations remained significant in multivariable analyses.

Key findings

  • In the clinically annotated cohort of 79 imatinib-treated CML patients, a higher number of mtDNA mutations (≥3) and higher variant allele frequency were associated with superior molecular responses, and these associations remained significant after multivariable adjustment.
“In a clinically annotated cohort of 79 imatinib-treated patients, a higher number of mtDNA mutations (≥3 mutations) and higher variant allele frequency were associated with superior molecular responses, and remained significant in multivariable analyses.”
2secondary dataDefine the somatic mtDNA mutational landscape in chronic-phase CML at diagnosis and relate mtDNA mutation burden/allele fraction to molecular response to imatinib in a clinically annotated cohort.secondary data / observational sequencing cohortExpand

In plain English

Comprehensive somatic mitochondrial DNA (mtDNA) profiling was performed at diagnosis in 120 patients with chronic‑phase chronic myeloid leukemia (CML). The study identified 241 somatic mtDNA mutations in 92 patients, of which 29 were reported as homoplasmic. Variant allele frequencies and mutation counts (including homoplasmy vs heteroplasmy classification) were estimated and summarized.

Key findings

  • In diagnostic samples from 120 chronic‑phase CML patients, 241 somatic mtDNA mutations were identified in 92 patients; 29 mutations were homoplasmic.241 somatic mtDNA mutations; 29 homoplasmic; mutations present in 92/120 patients
“We performed comprehensive profiling of somatic mtDNA mutations in 120 patients with chronic-phase CML.”
What this piece can’t prove
  • Abstract does not state whether matched germline controls were used to distinguish somatic from inherited mtDNA variants.

3 further details could not be confirmed from the summary.

3ex vivo humanLink mtDNA mutational patterns with distinct mitochondrial metabolic phenotypes/programs in CML CD34+ leukemic stem/progenitor cells, contrasting favorable vs suboptimal imatinib responders.ex vivo human metabolic phenotypingExpand

In plain English

In chronic-phase CML, somatic mtDNA mutational patterns in patient-derived CD34+ leukemic stem/progenitor cells are associated with distinct mitochondrial metabolic phenotypes that track with imatinib response status: suboptimal imatinib responders show features of enhanced oxidative phosphorylation (increased mitochondrial respiration, spare respiratory capacity, mitochondrial content, and enrichment of mitochondrial biogenesis and lipid metabolic programs), whereas favorable responders exhibit higher mtDNA mutational burden together with reduced respiratory reserve and increased mitophagy-related programs. Pharmacologic Complex I inhibition reduced clonogenic potential and increased imatinib sensitivity ex vivo. Separately, a higher number of mtDNA mutations (≥3) and higher variant allele frequency were associated with superior molecular responses in an imatinib-treated cohort.

Key findings

  • Suboptimal imatinib responders exhibited increased mitochondrial respiration, spare respiratory capacity, mitochondrial content, and enrichment of mitochondrial biogenesis and lipid metabolic programs, consistent with enhanced oxidative phosphorylation dependence.increased
  • Favorable responders displayed higher mtDNA mutational burden together with reduced respiratory reserve and increased mitophagy-related programs.higher mutational burden; reduced respiratory reserve
“mtDNA mutational patterns were associated with distinct metabolic phenotypes in CD34+ leukemic stem/progenitor cells.”
What this piece can’t prove
  • Ex vivo phenotyping of CD34+ cells may not fully capture in vivo tumor microenvironment effects or longitudinal treatment dynamics.

2 further details could not be confirmed from the summary.

4ex vivo humanTest whether pharmacologic mitochondrial Complex I inhibition impairs clonogenicity and enhances imatinib sensitivity (therapeutic vulnerability/combination rationale).ex vivo humanExpand

In plain English

Pharmacologic inhibition of mitochondrial Complex I reduced clonogenic potential and increased sensitivity to imatinib in CML cells; experiments are presented in the context of CD34+ leukemic stem/progenitor cell metabolic phenotypes.

Key findings

  • Pharmacologic Complex I inhibition reduced clonogenic potential and enhanced imatinib sensitivity.
“Pharmacologic Complex I inhibition reduced clonogenic potential and enhanced imatinib sensitivity.”
What this piece can’t prove
  • Unknown whether combination effects were formally modeled (e.g., synergy analysis) or represent additive effects.

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

05 / Asciminib (ABL001) in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Who Have Not Achieved a Deep Molecular Response With Long-Term Frontline Imatinib: A Randomized, Open-Label, Multicenter, Phase 2 Study

2018 · Crossref

Source (opens in a new tab)
Candidate

Imatinib in combination with cytarabine as compared to Imatinib alone in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study.

Http://isrctn.org/> · 2012 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.